In this Psychiatric Times Insights series, learn about key updates and clinical insights related to data presented at the 2026 ASCP Annual Meeting evaluating the safety and efficacy of transitioning patients from atypical antipsychotics to Cobenfy (xanomeline-trospium) using either a 2-week or 4-week cross-titration approach, and the practical guidance clinicians need to confidently make this switch in everyday practice.
